People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...
(Photo: CNA/Lim Li Ting) New: You can now listen to articles. SINGAPORE: Guidelines on screen use will be introduced in schools, including preschools, as part of a new national strategy launched ...
The Organisation for Economic Co-operation and Development (OECD) has a long-running process to address the tactics used by multinationals to cut their tax bills, achieved by moving profits around ...
Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide ... anesthesiologists is issuing new guidelines on proper use of ketamine.
A comprehensive new study confirmed that GLP-1 medications such as Ozempic and Mounjaro have myriad health benefits — even more than previously thought. Analyzing the medical records of roughly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback